Scanner DailyTickers — Saturday, June 21, 2026 — Special Small-Cap Edition

Aehr Test Systems is the purest small-cap play on the AI semiconductor testing boom. The company's FOX-XP and FOX-NP systems are critical for wafer-level burn-in testing of SiC (silicon carbide) and GaN (gallium nitride) chips — the power semiconductors driving EV, AI data center, and 5G infrastructure. Revenue grew 993% over the past year as every major chipmaker races to expand capacity. The stock hit an all-time high of $126.62 on June 15, then pulled back to $110 — creating a textbook momentum pullback entry at the 10-day EMA.

TG Therapeutics is executing a textbook biotech commercialization story with Briumvi (ublituximab), its anti-CD20 antibody for relapsing multiple sclerosis. Briumvi is gaining rapid market share against Ocrevus (Roche), with Q1 2026 revenue beating estimates and full-year guidance raised. The 52-week range is $25.28–$49.31, and the stock is consolidating just below its 52-week high — a classic breakout setup. The MS treatment market is $30B+ and Briumvi's differentiated subcutaneous formulation gives it a structural advantage.

Tango Therapeutics is surging on its synthetic lethality oncology platform, with the stock up 253% YTD and 46.8% in the last week alone. Wall Street analysts are hiking price targets aggressively. The company's lead program targets STK11-mutant NSCLC (non-small cell lung cancer), a large underserved population. The 7x gain over the past year reflects pipeline de-risking through clinical data readouts. The breakout above $25 on massive volume confirms institutional accumulation.

Celcuity's CELsignia diagnostic platform identifies cancer patients most likely to respond to targeted therapies — precision oncology's holy grail. The stock surged 1,116% over the past year from $7 to $88 on strong clinical data and FDA progress. The all-time high of $144.98 was hit May 4, 2026. The current consolidation near $88 (38% below ATH) represents a potential higher-low in the uptrend if the $74 support holds. Key catalyst: Phase 2 data readout expected Q3 2026.

SPX Technologies is a quality compounder benefiting from the US infrastructure modernization wave. The company makes HVAC systems, gas detection equipment, and power transformers — all in structural demand as data centers, EV charging, and grid modernization drive spending. Revenue grew 15.1% CAGR over 5 years, with EPS growing 23.6% CAGR. Recent earnings showed incremental margins expanding, indicating operating leverage kicking in. The stock is in a clean momentum channel above its 20-day and 50-day SMAs.

Luxfer is a UK-headquartered specialty materials company (NYSE-listed) making high-pressure gas cylinders, magnesium alloys, and carbon fiber composites for defense, healthcare (oxygen cylinders), and clean energy (hydrogen storage). At $515M market cap and $19/share, it's a genuine small-cap with 49.7% 1-year returns and improving fundamentals. The company benefits from three secular trends: hydrogen economy (cylinder demand), defense spending (military-grade materials), and healthcare infrastructure. The pullback to the 20-day SMA provides a lower-risk entry.

NuScale Power holds the only NRC-approved small modular reactor (SMR) design in the United States, giving it a massive first-mover advantage in the nuclear renaissance. Data center power demand is driving unprecedented interest in nuclear — Microsoft, Google, and Amazon have all announced nuclear power agreements. The analyst consensus target of $15.92 implies 35% upside. Short interest is declining as bears unwind, and institutional ownership is increasing. The $11–$12 range offers a technical entry near the ascending 50-day SMA.

Archer Aviation is the leading US eVTOL company with 112% analyst target upside ($11.83 consensus). The company is ramping production of its Midnight aircraft, with UAE operations and FAA type certification as near-term catalysts. Institutional ownership at 63% signals smart-money conviction. The 52-week range of $4.80–$14.62 suggests significant upside if production milestones are met. At $5.58, the stock is near the bottom of its range, offering an asymmetric risk/reward. Volume has picked up +3.35% on the session with above-average participation.

Opendoor is the contrarian play in this scan. The iBuyer platform took massive losses in 2022–2023 during the rate hike cycle but is now recovering as rates decline. At $4.47, the stock is priced for failure, yet institutional ownership sits at 63%, suggesting insiders see a path to profitability. The 3.75% Fed funds rate is the most favorable rate environment for housing since 2022. The company processes $10B+ in annual home transactions, and each 25bp rate cut directly increases home buying activity. The pullback to the 20-day SMA offers a defined-risk entry with a hard stop at $3.80.

IWM is the portfolio-level play on the small-cap rotation thesis without single-stock binary risk. The Russell 2000 is outperforming the S&P 500 for the first time in years, driven by rate cuts, fiscal tailwinds, and a valuation reset. The ETF provides exposure to 2,000 small-cap names diversified across sectors. The ascending trend above both 50-day and 200-day SMAs confirms the structural rotation. Russell reconstitution (June 27) creates a short-term catalyst as passive funds rebalance.